Nabriva Therapeutics (NASDAQ:NBRV) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Nabriva Therapeutics their estimated earnings by 12.5%, reporting an EPS of $-0.21 versus an estimate of $-0.24, which surprised analysts.
Revenue was up $7,571,000 from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.06, which was followed by a 0.86% increase in the share price the next day.
Here's a look at Nabriva Therapeutics's past performance:
| Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.35 | -0.67 | -0.95 | -1 |
| EPS Actual | -0.29 | -0.53 | -1.11 | -0.9 |
| Revenue Estimate | 5.99M | 2.25M | 600.00K | 450.00K |
| Revenue Actual | 8.24M | 2.53M | 2.46M | 1.29M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
